Review Articles - Influenza Antivirals

2015 - June 2020

Balasingam S, Wilder-Smith A. Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies.Int J Infect Dis. 2016 May 18. pii: S1201-9712(16)31056-6.  Full text 

Beard KR, Brendish NJ, Clark TW. Treatment of influenza with neuraminidase inhibitors. Curr Opin Infect Dis. 2018 Dec;31(6):514-519.Curr Opin Infect Dis. 2018 Dec;31(6):527-534.  Abstract 

Beigel JH. et al. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019 Apr 8;167:45-67.  Abstract

Beigel JH. Polyclonal and monoclonal antibodies for the treatment of influenza. Curr Opin Infect Dis. 2018 Dec;31(6):527-534.  Abstract

Boikos C. et al. Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15. J Antimicrob Chemother. 2017 Jun 1;72(6):1556-1573.  Abstract

Choe YJ. et al. Antiviral treatment of influenza in South Korea. Expert Rev Anti Infect Ther. 2015 Apr 3:1-9.  Abstract

Davidson S. Treating Influenza Infection, From Now and Into the Future. Front Immunol. 2018 Sep 10;9:1946.  Full text

Dobson J. et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015 Jan 29. pii: S0140-6736(14)62449-1.  Abstract

Hama R, Bennett CL. The mechanisms of sudden-onset type adverse reactions to oseltamivir. Acta Neurol Scand. 2016 Jun 30.  Full text

Hata A. et al. Safety and efficacy of peramivir for influenza treatment. Drug Des Devel Ther. 2014 Oct 24;8:2017-2038.  Full text

Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019 Apr;32(2):176-186. Full text

Heneghan CJ. et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess. 2016 May;20(42):1-242.  Full text 

Hsieh IN, Hartshorn KL. The Role of Antimicrobial Peptides in Influenza Virus Infection and Their Potential as Antiviral and Immunomodulatory Therapy. Pharmaceuticals (Basel). 2016 Sep 6;9(3). pii: E53.  Full text

Hui DS. et al. The role of adjuvant immunomodulatory agents for treatment of severe influenza. (Hong Kong) Antiviral Res. 2018 Feb;150:202-216. Epub 2018 Jan 8.  Abstract

Hussain M. et al. Drug resistance in influenza A virus: the epidemiology and management. Infect Drug Resist. 2017 Apr 20;10:121-134.  Full text  

Ide K. Anti-Influenza Virus Effects of Catechins: A Molecular and Clinical Review. Curr Med Chem. 2016 Nov 22.  Abstract

Ide K, Yamada H, Kawasaki Y. Effect of gargling with tea and ingredients of tea on the prevention of influenza infection: a meta-analysis. BMC Public Health. 2016 May 12;16(1):396.  Full text

Ison MG. Optimizing antiviral therapy for influenza: understanding the evidence.Expert Rev Anti Infect Ther. 2015 Feb 19:1-9. Abstract

Jagannath VA. et al. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Cochrane Database Syst Rev. 2016 Feb 24;2:CD008139.  Full text

Lee J. Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis. Yonsei Med J. 2017 Jul;58(4):778-785.  Full text

Lee N, Hurt AC. Neuraminidase inhibitor resistance in influenza: a clinical perspective. Curr Opin Infect Dis. 2018 Dec;31(6):520-526.  Abstract

Li TC, Chan MC, Lee N. Clinical Implications of Antiviral Resistance in Influenza. Viruses. 2015 Sep 14;7(9):4929-44.  Full text

McLaughlin MM, Skoglund EW, Ison MG. Peramivir : an intravenous neuraminidase inhibitor. Expert Opin Pharmacother. 2015 Aug;16(12):1889-900.  Abstract

McMahon A, Martin-Loeches I. The pharmacological management of severe influenza infection - 'existing and emerging therapies'. Expert Rev Clin Pharmacol. 2016 Nov 25:1-15.  Abstract

Malosh RE. et al. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clin Infect Dis. 2018 May 2;66(10):1492-1500.  Abstract

Mifsud EJ. et al. Animal models used to assess influenza antivirals. Expert Opin Drug Discov. 2018 Oct 26:1-9.  Abstract

Muthuri SG. et al. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an IPD meta-analysis. Influenza Other Respir Viruses. 2015 Nov 25.  Full text

Naesens L, Stevaert A, Vanderlinden E. Antiviral therapies on the horizon for influenza. Curr Opin Pharmacol. 2016 Aug 25;30:106-115.  Full text

Pizzorno A. et al. Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy. Front Immunol. 2019 Mar 19;10:531.  Full text

Shie JJ, Fang JM.  Development of effective anti-influenza drugs: congeners and conjugates - a review.  J Biomed Sci. 2019 Oct 23;26(1):84.   Full Text

Shin WJ, Seong BL. Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery. Expert Opin Drug Discov. 2013 Apr;8(4):411-26.  Abstract

Skalickova S. et al. Perspective of Use of Antiviral Peptides against Influenza Virus. Viruses. 2015 Oct 20;7(10):5428-42.  Full text

Smith LE. et al. A systematic review of factors affecting intended and actual adherence with antiviral medication as treatment or prophylaxis in seasonal and pandemic flu. Influenza Other Respir Viruses. 2016 Jul 11.  Full text

Taieb V. et al. A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients. Curr Med Res Opin. 2019 Feb 27:1.  Abstract

Tanner EJ, Kirkegaard KA, Weinberger LS. Exploiting Genetic Interference for Antiviral Therapy.PLoS Genet. 2016 May 5;12(5):e1005986.  Full text

van de Wakker SI, Fischer MJE, Oosting RS. New drug-strategies to tackle viral-host interactions for the treatment of influenza virus infections. Eur J Pharmacol. 2017 May 19. pii: S0014-2999(17)30370-9.  Full text

Watanabe T, Kawaoka Y. Influenza virus-host interactomes as a basis for antiviral drug development. Curr Opin Virol. 2015 Oct;14:71-8. Abstract

Wester A, Shetty AK. Peramivir injection in the treatment of acute influenza: a review of the literature. Infect Drug Resist. 2016 Aug 22;9:201-14. Full text

Yang HT. et al. Translating genomic sequences into antibody efficacy and safety against influenza toward clinical trial outcomes: a case study. (Taiwan) Drug Discov Today. 2016 Jun 15. pii: S1359-6446(16)30226-4. Abstract

Yen HL. Current and novel antiviral strategies for influenza infection. Curr Opin Virol. 2016 Jun 23;18:126-134. Abstract

Zhou X. Citations alone were enough to predict favorable conclusions in reviews of neuraminidase inhibitors. J Clin Epidemiol. 2015 Jan;68(1):87-93. Full text